January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for

2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

our strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer, CEO of Addex.

Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.

: the present as prologue Industry News Exscientia Business Update for Third Quarter 2023 Addex CEO Tim Dyer to Discuss Allosteric Modulators in Neurological Disorders at Jefferies Healthcare Conference in

Ben Myers!

Receptor (GIPR) Revealed by Trapped-Ion-Mobility Spectrometry Coupled to Time-of-Flight Mass Spectrometry (TIMS-TOF

which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer

Quantitative analysis of sterol-modulated monomer-dimer equilibrium of the β1-adrenergic receptor by DEER

Quantitative analysis of sterol-modulated monomer-dimer equilibrium of the β1-adrenergic receptor by DEER

H. 2020, Casiraghi, M. et al. 2019), double electron-electron resonance (DEER) spectroscopy for high-resolution

.; Iyer, M. R.; Cinar, R.; Coffey, N. ; Beck, J.; Nettekoven, M.; Benito-Cuesta, I.; Grande, T.; Drawnel, F.; Widmer, G.; Holzer, D.; Van Der V.; Van Der Stelt, M.; Pacher, P.; Gertsch, J.; Ullmer, C.; McCormick, P. J.; Oddi, S.; Spaink, H.